PAKISTAN INSULIN STUDY (PINS) GLYCEMIC VARIABILITY AND EFFICACY OF NEW INSULINS IN TYPE 2 DIABETES
Main Article Content
Keywords
Efficacy, Glargine, Degludec, Hyderabad, Diabetes
Abstract
Introduction: Type 2 diabetes is alarmingly increasing all over the globe. The oral anti diabetics and old insulins are frequently used by patients and doctors but exhibited high glycemic variability and more side effects profile. The newer insulins are better in term of reducing future complications.
Objective: To evaluate and assess the glycemic variability of new insulins in type 2 diabetes mellitus attended OPD of Liaquat University Hospital Hyderabad / Jamshoro Sindh, Pakistan
Study Design& duration: Randomized control trial.
Study Setting: OPDs of Liaquat University Hospital Hyderabad / Jamshoro Pakistan
Duration of Study: September 20 2023to January 2024
Methodology: All patients with type 2 DM for at least 4 years duration, already taking mixed insulin with or without Oral antidiabetic with age limit from 30-59 years of either gender were randomized by open clinical random software. Three insulin, Glargine 100, Glargine 300 and degludec have been studied. The glycemic variability of <50mg /dl and reduction in HbA1c of at least ≥0.5% from the baseline, at 3 months was considered as less glycemic variability and efficacious.
Results: Of 76 patients, the mean age was 41.24 ±4.89 years. There were 40 (66.7%) females and 36 (33.3%) males. The mean BMI was26±1,4kg/m2 respectively. The mean pre and post HbA1c level were 7.78 ±1.43 and 6.73 ±1.39 respectively. Nine patients (12%) have shown reduction of HbA1c from 0.5 to 1% in 3 months, p value was 0.005 . Weight reduction was not significant in three groups. The less glycemic variability is shown in Glargine 300 p value 0.003 and degludec group 0.07
Conclusion: There was less glycemic variability and reduction of HbA1c was found Glargine 300 and Degludec using patients. All three insulins had better profile than pre mixed insulins.
References
2. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: A retrospective cohort study. BMJ Open (2016) 6(1):e010210. doi: 10.1136/bmjopen-2015-010210
3. Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA - J Am Med Assoc (2014) 311(22):2315–25. doi: 10.1001/jama.2014.5951
4. Garg SK, Rewers AH, Akturk HK. Ever-increasing insulin-requiring patients globally. Diabetes Technol Ther. 2018;20:S21-24.
5. Battelino T, Bosnyak Z, Danne T, et al. In Range: comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring–study design. Diabetes Ther. 2020;11:1017–27.
6. Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T. Concentrated insulins in current clinical practice. Diabetes Res Clin Pract. 2019;148:93–101.
7. Zizzari AT, Pliatsika D, Gall FM,et al. New perspectives in oral peptide delivery. Drug Discov Today. 2021; 26:1097–105
8. Mehta R, Chen R, Hirose T, et al. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes Obes Metab. 2020; 22:1961–75
9. Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53:998–1009.
10. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191–204
11. Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017;318(1):45–56
12. Nasrallah SN, Reynolds LR. Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? Clin Med Insights Endocrinol Diabetes. 2012;5:31–7
13. Linnebjerg H, Lam ECQ, Zhang X, et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes Metab. 2017;19(1):33–9.
14. Vargas-Uricoechea H. Efficacy and safety of insulin glargine 300 U/mL versus 100 U/mL in diabetes mellitus: a comprehensive review of the literature. J Diabetes Res. 2018;2018:2052101.
15. Van den Berghe G, Wouters , et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67
16. Monnier L, Colette C. Glycemic variability. Should we and can we prevent it? Diabetes Care. 2008;31(Suppl 2):S150–4
17. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239–44.
18. Gorst C, Kwok CS, Aslam S et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–69.
19. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253–63.
20. Aamir AH, Ul-Haq Z, Mahar SA et al . Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan. BMJ Open. 2019 Feb 21;9(2):e025300.
21. Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabetes/Metab Res Rev (2009) 25:S4–10. doi: 10.1002/dmrr.981
22. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13:614‐626
23. Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes care. 2017;40(6):777–83.
24. Yokota S, Tanaka H, Mochizuki Y et al. Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18(1):166.
25. Julio Rosenstock, Alice Cheng, Robert et al. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care 1 October 2018; 41 (10): 2147–2154
26. Becker RH, Dahmen R, Bergmann et al. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015 Apr;38(4):637-43.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Imran Ali Shaikh
FCPS, FACP, FRCP, FPSIM, Professor of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan
Dr. Javeria Hameed Shaikh
MBBS, M Phil, Lecturer, Department of Physiology, Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan
Dr. Karman Qureshi
Senior Lecturer, Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan
Dr. Nargis Khan
Assistant Professor FCPS, Dow University of Health Sciences, Ojha Campus, Karachi
Dr. Naila Masood
MD, FACP, FRCP, FPSIM, Professor of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro Sind, Pakistan
Dr. Sobia Karamullah
FCPS, Assistant Professor of Medicine, Liaquat University of Medical and Health Sciences (LUMHS) Jamshoro Sind, Pakistan